Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and
accounts for> 90% of cancers in the kidney. The disease encompasses> 10 histological and …

Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned
from a nonspecific immune approach (in the cytokine era), to targeted therapy against …

PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

Background Cytoreductive nephrectomy has been the standard of care in metastatic renal-
cell carcinoma for 20 years, supported by randomized trials and large, retrospective studies …

Importance In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC)
have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the …

Kidney cancers have been extensively studied, and insights from an increased
understanding of tumor biology have led to increases in survival rates. Therapies aimed at …

Importance The National Cancer Database (NCDB), a joint quality improvement initiative of
the American College of Surgeons Commission on Cancer and the American Cancer …

Sarcomatoid dedifferentiation is an uncommon feature that can occur in most histological
subtypes of renal cell carcinomas (RCCs) and carries a decidedly poor prognosis …

Background The randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib
as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor risk met …

Context The role of cytoreductive nephrectomy (CN) in the management of metastatic renal
cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. Objective To assess …